Supriya Lifescience Limited
836.25
INR
-6.35
(-0.75%)
ISIN
INE07RO01027
Return %
Stock
S&P 500
1Y
10.89
14.20
3Y
238.84
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Satish Waman Wagh
- Full Time Employees
- 1,310
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 207/208 Udyog Bhavan Mumbai MH India 400063
- IPO Date
- Dec 28, 2021
- Website
- supriyalifescience.com
- Similar Companies
- Business
- Supriya Lifescience Limited is a Mumbai-headquartered Indian pharmaceutical company founded in 1987 that specializes in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). The company’s product portfolio encompasses over 40 APIs and spans therapeutic segments including anti-histamines, anti-allergics, analgesics, anti-pyretics, anesthetics, anti-asthmatics, anti-hypertensives, anti-malarials, vitamins, anti-gout products, oncology, veterinary APIs, and general category pharmaceuticals. Supriya also offers specialized products such as GelHeal, a wound care solution, and Quickblue, an oral cancer detection kit. It focuses on complex chemistries, controlled substances, and backward integrated manufacturing with USFDA, EDQM/EUGMP, Health Canada, and NMPA certifications at its state-of-the-art facility in Maharashtra, India, supporting global exports. Recent developments include strategic collaborations and expansions such as a partnership with Plasma Nutrition Inc. for exclusive manufacturing and marketing rights of Ingredient Optimized Protein (ioProtein) in India, and agreements with Kalinga Institute of Technology to enhance the development of its wound healing gel GelHeal and the novel oral cancer detection kit Quickblue, for which it has filed patents. Supriya is also advancing contract manufacturing organization (CMO) projects, including a key long-term exclusive API supply contract with a leading European pharmaceutical company expected to generate peak revenues of Rs 40 crore from FY27. The company has expanded its product portfolio into new therapeutic areas like anti-allergic, anti-anxiety, contrast media, and nutraceuticals, with regulatory permissions for whey protein production and formulation manufacturing ramping up at its Ambernath facility. These initiatives align with its growth strategy to reduce reliance on specific therapies and leverage the "China+1" supply chain advantage in global markets. Supriya Lifescience operates primarily in the pharmaceutical manufacturing sector with a strong global distribution footprint. The company navigates various market segments by targeting chronic and specialty drug markets with a commitment to innovation and expanding its therapeutic offerings and manufacturing capabilities to serve multinational companies, innovators, and generic pharmaceutical markets worldwide. It positions itself as a reliable partner in the global pharmaceutical supply chain with an emphasis on regulatory compliance, backward integration, and complex API development to maintain competitiveness and growth. This description reflects Supriya Lifescience Limited’s comprehensive capabilities in pharmaceutical ingredient manufacturing, ongoing innovation and product development, strategic partnerships to drive new product launches and market expansion, and its operational growth with enhanced production capacity and global contract manufacturing deliveries as of late 2025.